May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
May 21, 2018 - Achaogen breaks key support.Aimmune Therapeutics is a buy.Immune Design keeps its head above water.
May 19, 2018 - Immune Design and Viking Therapeutics are added to the win column.Exelixis makes up for its lost ground and is grounded on concrete support.As predicted, shares in Global Blood Therapeutics bled late
May 16, 2018 - Immune Design is beginning to run.Institutions place their bets on Viking Therapeutics. We will also do so, again.Array BioPharma becomes our second win.ChemoCentryx seems undervalued.
May 14, 2018 - Although this series is focused on the long term I continue to be pleased with our performance so far.President Trump´s speech on drug prices removed a key overhang for biotech (please see my blog pos
May 14, 2018 - We have reasons to believe Achaogen will bounce back and resume its upward momentum. In anticipation of this, Achaogen will replace Omeros in the Lucky Seven portfolio. Shares in Global Blood Therapeu
May 12, 2018 - Viking Therapeutics faces key resistance.Omeros reports Q1 earnings - continues its strong ascent.Array BioPharma springs off support.Exelixis, in collaboration with Roche, failed a phase 3 trial. The
May 11, 2018 - Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
May 09, 2018 - Array BioPharma (NASDAQ:ARRY) Q3 2018 Earnings Conference Call May 9, 2018 9:00 AM ET Executives Andrea Flynn - Senior Director, Investor Relations and Corporate Communications Ron Squarer - Chief Exe
May 09, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with their 2018 Q3 earnings call.